<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="tyrosinemia" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">tyrosinemia</book-part-id>
      <title-group>
        <title>Tyrosinemia Type I</title>
        <alt-title alt-title-type="alt-title">Synonyms: FAH Deficiency, Fumarylacetoacetase Deficiency, Fumarylacetoacetate Hydrolase Deficiency, Hepatorenal Tyrosinemia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sniderman King</surname>
            <given-names>Lisa</given-names>
          </name>
          <degrees>MSc, CGC</degrees>
          <aff>Genzyme Corporation<break/>Cambridge, Massachusetts</aff>
          <email>lisa.snidermanking@genzyme.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Trahms</surname>
            <given-names>Cristine</given-names>
          </name>
          <degrees>MS, RD</degrees>
          <aff>Department of Nutrition<break/>University of Washington<break/>Seattle, Washington</aff>
          <email>ctrahms@u.washington.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Scott</surname>
            <given-names>C Ronald</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Pediatrics<break/>University of Washington<break/>Seattle, Washington</aff>
          <email>crscott@u.washington.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>24</day>
          <month>7</month>
          <year>2006</year>
        </date>
        <date date-type="updated">
          <day>25</day>
          <month>5</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="thdrd" document-type="chapter">Tyrosine Hydroxylase Deficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="unc80-def" document-type="chapter">UNC80 Deficiency</related-object>
      <abstract id="tyrosinemia.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Untreated tyrosinemia type I usually presents either in young infants with severe liver involvement or later in the first year with liver dysfunction and renal tubular dysfunction associated with growth failure and rickets. Untreated children may have repeated, often unrecognized, neurologic crises lasting one to seven days that can include change in mental status, abdominal pain, peripheral neuropathy, and/or respiratory failure requiring mechanical ventilation. Death in the untreated child usually occurs before age ten years, typically from liver failure, neurologic crisis, or hepatocellular carcinoma. Combined treatment with nitisinone and a low-tyrosine diet has resulted in a greater than 90% survival rate, normal growth, improved liver function, prevention of cirrhosis, correction of renal tubular acidosis, and improvement in secondary rickets.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Tyrosinemia type I results from deficiency of the enzyme fumarylacetoacetase (FAH). The diagnosis is established in a proband with typical biochemical findings (increased succinylacetone concentration in the blood and urine; elevated plasma concentrations of tyrosine, methionine, and phenylalanine; and elevated urinary concentration of tyrosine metabolites and the compound &#x003b4;-ALA) and/or by the identification of biallelic pathogenic variants in <italic toggle="yes">FAH</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Nitisinone (Orfadin<sup>&#x000ae;</sup>), 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC), which blocks parahydroxyphenylpyruvic acid dioxygenase <italic toggle="yes">(p</italic>-HPPD), the second step in the tyrosine degradation pathway, prevents the accumulation of fumarylacetoacetate and its conversion to succinylacetone. Nitisinone treatment should begin as soon as the diagnosis of tyrosinemia type I is confirmed. Because nitisinone increases the blood concentration of tyrosine, dietary management with controlled intake of phenylalanine and tyrosine should be started immediately after diagnosis to prevent tyrosine crystals from forming in the cornea. If the blood concentration of phenylalanine becomes too low (&#x0003c;20 &#x003bc;mol/L), additional natural protein should be added to the diet. Prior to the availability of nitisinone, the only definitive therapy for tyrosinemia type I was liver transplantation, which now should be reserved for those children who have severe liver failure at presentation and fail to respond to nitisinone therapy or have documented evidence of malignant changes in hepatic tissue.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Initiation of treatment with nitisinone as soon as the diagnosis is confirmed.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Treatment of early signs of carnitine deficiency, osteoporosis, and rickets that are secondary to renal tubular Fanconi syndrome.</p>
          <p><italic toggle="yes">Surveillance:</italic> Guidelines for routine surveillance of individuals with tyrosinemia type I have been established.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Inappropriate protein intake.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> All subsequent children of the parents of a child with tyrosinemia type I should have urine and blood succinylacetone analyzed as soon as possible after birth to enable the earliest possible diagnosis and initiation of therapy. If the pathogenic variants in the family are known, prenatal molecular genetic testing of an at-risk pregnancy may be considered.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Little data exist on the use of nitisinone during human pregnancy; however, at least two women have given birth to healthy infants while receiving therapeutic doses of nitisinone.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Tyrosinemia type I is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants in a family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="tyrosinemia.Diagnosis">
        <title>Diagnosis</title>
        <p>Tyrosinemia type I is caused by deficiency of the enzyme fumarylacetoacetase (FAH) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://enzyme.expasy.org/EC/3.7.1.2">EC 3.7.1.2</ext-link>) (see <xref ref-type="fig" rid="tyrosinemia.F1">Figure 1</xref> and <xref ref-type="sec" rid="tyrosinemia.Pathophysiology">Pathophysiology</xref>).</p>
        <sec id="tyrosinemia.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Tyrosinemia type I <bold>should be suspected</bold> in individuals with the following newborn screening results, clinical features, and supportive laboratory findings.</p>
          <p>
            <bold>Newborn screening</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Presence of succinylacetone,</bold> measured directly from the newborn blood spot by tandem mass spectroscopy, is pathognomonic for tyrosinemia type 1.</p>
            </list-item>
            <list-item>
              <p><bold>Elevated tyrosine or methionine concentration</bold> in the blood suggests liver disease, which can be from a variety of causes; the diagnosis of tyrosinemia type I should be further evaluated by quantification of plasma or urinary succinylacetone.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Infants with tyrosinemia type I may have only modestly elevated or normal blood concentrations of tyrosine and methionine when the first newborn screening sample is collected.</p>
                </list-item>
                <list-item>
                  <p>Elevated tyrosine concentration on newborn screening can be the result of transient tyrosinemia of the newborn, tyrosinemia type II or III, or other liver disease.</p>
                </list-item>
                <list-item>
                  <p>Elevated methionine concentration can indicate liver dysfunction, defects in methionine metabolism, or homocystinuria (see <related-object link-type="booklink" source-id="gene" document-id="homocystinuria" document-type="chapter">Homocystinuria Caused by Cystathionine Beta-Synthetase Deficiency</related-object>).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Low delta-ALA-dehydratase (PBG synthase) enzyme activity.</bold> This is measured in the newborn screening program in Quebec, Canada [<xref ref-type="bibr" rid="tyrosinemia.REF.gigu_re.2005">Gigu&#x000e8;re et al 2005</xref>]. Succinylacetone is then measured in the urine of infants with apparent &#x003b4;-ALA dehydratase deficiency [<xref ref-type="bibr" rid="tyrosinemia.REF.schulze.2001.1424">Schulze et al 2001</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Clinical features (in untreated individuals)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Severe liver disease in young infants</p>
            </list-item>
            <list-item>
              <p>Signs of renal disease, rickets, and/or neurologic crises in children older than age six months</p>
              <p>Untreated children may have repeated neurologic crises lasting one to seven days that can include change in mental status, abdominal pain, peripheral neuropathy, and/or respiratory failure requiring mechanical ventilation.</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Increased succinylacetone concentration in the blood and excretion in the urine</bold>
              </p>
              <p>Note: (1) Increased excretion of succinylacetone in the urine of a child with liver failure or severe renal disease is a pathognomonic sign of tyrosinemia type I. (2) Many laboratories require that measurement of succinylacetone be specifically requested when ordering urine organic acids.</p>
            </list-item>
            <list-item>
              <p>
                <bold>Elevated plasma concentration of tyrosine, methionine, and phenylalanine</bold>
              </p>
              <p>Note: (1) Plasma tyrosine concentration in affected infants can be normal in cord blood and during the newborn period. (2) Elevated plasma tyrosine concentration can also be a nonspecific indicator of liver damage or immaturity; for example, in infants taking a high-protein formula [<xref ref-type="bibr" rid="tyrosinemia.REF.techakittiroj.2005.281">Techakittiroj et al 2005</xref>], including undiluted goat's milk [<xref ref-type="bibr" rid="tyrosinemia.REF.hendriksz.2004.552">Hendriksz &#x00026; Walter 2004</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Elevated urinary concentration of tyrosine metabolites</bold>
<italic toggle="yes">p</italic>-hydroxyphenylpyruvate, <italic toggle="yes">p</italic>-hydroxyphenyllactate, and <italic toggle="yes">p</italic>-hydroxyphenylacetate detected on urine organic acid testing</p>
            </list-item>
            <list-item>
              <p><bold>Increased urinary excretion of the compound &#x003b4;-ALA</bold> secondary to inhibition of the enzyme &#x003b4;-ALA dehydratase by succinylacetone in the liver and circulating red blood cells [<xref ref-type="bibr" rid="tyrosinemia.REF.sassa.1983.625">Sassa &#x00026; Kappas 1983</xref>]</p>
            </list-item>
            <list-item>
              <p>
                <bold>Changes in liver function (in untreated tyrosinemia type 1)</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Markedly elevated serum concentration of alpha-fetoprotein (average 160,000 ng/mL)</bold> (normal: &#x0003c;1000 ng/mL for infants age 1-3 months; &#x0003c;12 ng/mL for children age 3 months to 18 years)</p>
                </list-item>
                <list-item>
                  <p>Prolonged prothrombin and partial thromboplastin times</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: (1) Changes in serum concentration of alpha-fetoprotein (AFP) and prothrombin time/partial thromboplastin time (PT/PTT) are more severe in tyrosinemia type I than in nonspecific liver disease and are often the presenting findings in tyrosinemia type I. (2) Transaminases and bilirubin are only modestly elevated, if at all. (3) An individual with liver disease and normal serum concentration of AFP and normal PT/PTT has a low probability of having tyrosinemia type I.</p>
        </sec>
        <sec id="tyrosinemia.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of tyrosinemia type I <bold>is established</bold> in a proband with characteristic biochemical findings (increased succinylacetone concentration in the blood and urine; elevated plasma concentrations of tyrosine, methionine, and phenylalanine; and elevated urinary concentration of tyrosine metabolites and the compound &#x003b4;-ALA) and/or by the identification of biallelic pathogenic variants in <italic toggle="yes">FAH</italic> on molecular genetic testing (see <xref ref-type="table" rid="tyrosinemia.T.molecular_genetic_testing">Table 1</xref>).</p>
          <sec id="tyrosinemia.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">FAH</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            <list list-type="bullet">
              <list-item>
                <p>Targeted analysis for the <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">p.Pro261Leu</xref> pathogenic variant can be performed first in individuals of Ashkenzai Jewish ancestry; this variant accounts for more than 99% of the pathogenic variants in this population [<xref ref-type="bibr" rid="tyrosinemia.REF.elpeleg.2002.80">Elpeleg et al 2002</xref>].</p>
              </list-item>
              <list-item>
                <p>The pathogenic variant <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.1062+5G&#x0003e;A (IVS12+5 G&#x0003e;A)</xref> accounts for 87.9% of pathogenic variants in the French Canadian population [<xref ref-type="bibr" rid="tyrosinemia.REF.poudrier.1996.59">Poudrier et al 1996</xref>].</p>
              </list-item>
              <list-item>
                <p>The four common <italic toggle="yes">FAH</italic> pathogenic variants &#x02013; c.1062+5G&#x0003e;A (IVS12+5 G&#x0003e;A), <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.554-1G&#x0003e;T</xref> (IVS6-1 G&#x0003e;T), <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.607-6T&#x0003e;G</xref> (IVS7-6 T&#x0003e;G), and p.Pro261Leu &#x02013; account for approximately 60% of pathogenic variants in tyrosinemia type I in the general US population [CR Scott, unpublished data].</p>
              </list-item>
            </list>
            <table-wrap id="tyrosinemia.T.molecular_genetic_testing" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Tyrosinemia Type I</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">FAH</italic>
                    </td>
                    <td headers="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_tyrosinemia.T.molecular_genetic_testing_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown; one reported large deletion&#x000a0;<sup>5</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="tyrosinemia.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="tyrosinemia" object-id="tyrosinemia.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="tyrosinemia.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="tyrosinemia.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="tyrosinemia.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="tyrosinemia.TF.1.4">
                  <label>4. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="tyrosinemia.TF.1.5">
                  <label>5. </label>
                  <p><xref ref-type="bibr" rid="tyrosinemia.REF.park.2009.930">Park et al [2009]</xref> reported a large deletion involving <italic toggle="yes">FAH.</italic></p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="tyrosinemia.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="tyrosinemia.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>For children who were not detected by newborn screening, tyrosinemia type I</bold> usually presents either in young infants with severe liver involvement or later in the first year with liver dysfunction and significant renal involvement, growth failure, and rickets. Growth failure results from chronic illness with poor nutritional intake, liver involvement, and/or chronic renal disease. Death in the undetected or untreated child usually occurs before age ten years, typically from liver failure, neurologic crisis, or hepatocellular carcinoma.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Liver involvement.</bold> Undetected or untreated children presenting before age six months typically have acute liver failure with initial loss of synthetic function for clotting factors. PT and PTT are markedly prolonged and not corrected by vitamin K supplementation; factor II, VII, IX, XI, and XII levels are decreased; factor V and factor VIII levels are preserved. Paradoxically, serum transaminase levels may be only modestly elevated; serum bilirubin concentration may be normal or only slightly elevated, in contrast to most forms of severe liver disease in which marked elevation of transaminases and serum bilirubin concentration occur <bold>concomitantly</bold> with prolongation of PT and PTT. Resistance of affected liver cells to cell death may explain the observed discrepancy in liver function [<xref ref-type="bibr" rid="tyrosinemia.REF.vogel.2004.433">Vogel et al 2004</xref>].</p>
              <p>This early phase can progress to liver failure with ascites, jaundice, and gastrointestinal bleeding. Children may have a characteristic odor of "boiled cabbage" or "rotten mushrooms." Infants occasionally have persistent hypoglycemia; some have hyperinsulinism [<xref ref-type="bibr" rid="tyrosinemia.REF.baumann.2005.131">Baumann et al 2005</xref>]. Others have chronic low-grade acidosis [CR Scott, unpublished data]. Untreated affected infants may die from liver failure within weeks or months of first symptoms [<xref ref-type="bibr" rid="tyrosinemia.REF.hegarty.2015.1387">Hegarty et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Renal tubular involvement.</bold> In the more chronic form of the untreated disorder, symptoms develop after age six months; renal tubular involvement is the major manifestation. The renal tubular dysfunction involves a Fanconi-like renal syndrome with generalized aminoaciduria, phosphate loss, and, for many, renal tubular acidosis. The continued renal loss of phosphate is believed to account for rickets; serum calcium concentrations are usually normal.</p>
            </list-item>
            <list-item>
              <p><bold>Neurologic crises.</bold> Untreated children may have repeated neurologic crises similar to those seen in older individuals with <related-object link-type="booklink" source-id="gene" document-id="aip" document-type="chapter">acute intermittent porphyria</related-object>. These crises include change in mental status, abdominal pain, peripheral neuropathy, and/or respiratory failure requiring mechanical ventilation. Crises can last one to seven days. Repeated neurologic crises often go unrecognized:</p>
              <list list-type="bullet">
                <list-item>
                  <p><xref ref-type="bibr" rid="tyrosinemia.REF.mitchell.1990.432">Mitchell et al [1990]</xref> reported that 42% of untreated French Canadian children with tyrosinemia type I had experienced such episodes.</p>
                </list-item>
                <list-item>
                  <p>In an international survey, <xref ref-type="bibr" rid="tyrosinemia.REF.van_spronsen.1994.1187">van Spronsen et al [1994]</xref> reported that 10% of deaths in untreated children occurred during a neurologic crisis.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Hepatocellular carcinoma.</bold> Those children who are not treated with nitisinone and a low-tyrosine diet and who survive the acute onset of liver failure are at high risk of developing and succumbing to hepatocellular carcinoma.</p>
            </list-item>
            <list-item>
              <p><bold>Survival in untreated children.</bold> Untreated infants diagnosed before age two months had a two-year survival rate of 29% [<xref ref-type="bibr" rid="tyrosinemia.REF.van_spronsen.1994.1187">van Spronsen et al 1994</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Those diagnosed between ages two and six months had a 74% two-year survival rate; those diagnosed after age six months had a 96% two-year survival rate.</p>
                </list-item>
                <list-item>
                  <p>After more than five years the survival rate of the group diagnosed between ages two and six months dropped to approximately 30% and that of the group diagnosed after age six months dropped to approximately 60% (<xref ref-type="fig" rid="tyrosinemia.F2">Figure 2</xref>).</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Treated tyrosinemia type I.</bold> The natural history in children who are treated with nitisinone is different from that in untreated children. Affected children younger than age two years who are treated with a combination of nitisinone and low-tyrosine diet are markedly improved compared to those children treated with low-tyrosine diet alone. The combined nitisinone and low-tyrosine diet treatment has resulted in a greater than 90% survival rate, normal growth, improved liver function, prevention of cirrhosis, correction of renal tubular acidosis, and improvement in secondary rickets [<xref ref-type="bibr" rid="tyrosinemia.REF.mckiernan.2006.743">McKiernan 2006</xref>, <xref ref-type="bibr" rid="tyrosinemia.REF.masurelpaulet.2008.81">Masurel-Paulet et al 2008</xref>, <xref ref-type="bibr" rid="tyrosinemia.REF.larochelle.2012.49">Larochelle et al 2012</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Neurologic crises</bold> observed in treated children have always been associated with a prolonged interruption in nitisinone treatment [CR Scott, unpublished data].</p>
            </list-item>
            <list-item>
              <p>Children with <bold>acute liver failure</bold> require support prior to and during the initiation of treatment with nitisinone. Improvement generally occurs within one week of starting nitisinone treatment.</p>
            </list-item>
            <list-item>
              <p><bold>Corneal crystals.</bold> Nitisinone blocks the tyrosine catabolic pathway such that succinylacetone is not produced but tissue tyrosine levels are raised. Blood tyrosine concentration greater than 600 mol/L confers risk of precipitation of tyrosine as bilateral, linear, branching subepithelial corneal opacities [<xref ref-type="bibr" rid="tyrosinemia.REF.ahmad.2002.266">Ahmad et al 2002</xref>], causing photophobia and itchy, sensitive eyes. The crystals resolve once tyrosine levels are reduced.</p>
            </list-item>
            <list-item>
              <p><bold>Hepatocellular carcinoma.</bold> Although <xref ref-type="bibr" rid="tyrosinemia.REF.holme.2000.805">Holme &#x00026; Lindstedt [2000]</xref> and <xref ref-type="bibr" rid="tyrosinemia.REF.van_spronsen.2005.90">van Spronsen et al [2005]</xref> reported hepatocellular carcinoma in individuals after years of nitisinone therapy, it is estimated that fewer than 5% of children placed on nitisinone therapy before age two years develop hepatocellular carcinoma by age ten years [<xref ref-type="bibr" rid="tyrosinemia.REF.larochelle.2012.49">Larochelle et al 2012</xref>].</p>
              <p>In Quebec, where tyrosinemia type I is included in the newborn screening program, no affected individuals have been hospitalized for manifestations of tyrosinemia type I, and hepatocellular carcinoma has not been reported in individuals who were placed on nitisinone therapy prior to age 30 days. The longest period of treatment reported in this group is 12 years [<xref ref-type="bibr" rid="tyrosinemia.REF.larochelle.2012.49">Larochelle et al 2012</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="tyrosinemia.Pathophysiology">
          <title>Pathophysiology</title>
          <p>Fumarylacetoacetase (FAH) is the terminal enzyme in the tyrosine catabolic pathway (<xref ref-type="fig" rid="tyrosinemia.F1">Figure 1</xref>). In FAH deficiency, fumarylacetoacetate (FAA), the immediate precursor:</p>
          <list list-type="bullet">
            <list-item>
              <p>Appears to accumulate in hepatocytes, causing cellular damage and apoptosis (identified in an animal model by <xref ref-type="bibr" rid="tyrosinemia.REF.endo.2002.227">Endo &#x00026; Sun [2002]</xref>);</p>
            </list-item>
            <list-item>
              <p>Is diverted into succinylacetoacetate and succinylacetone. Succinylacetone interferes with the activity of the following hepatic enzymes:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Parahydroxyphenylpyruvic acid dioxygenase <italic toggle="yes">(p</italic>-HPPD), resulting in elevation of plasma tyrosine concentration;</p>
                </list-item>
                <list-item>
                  <p>PBG synthase, resulting in (1) reduced activity of the enzyme &#x003b4;-ALA dehydratase in liver and circulating red blood cells; (2) reduced heme synthesis; (3) increased &#x003b4;-aminolevulinic acid (&#x003b4;-ALA), which may induce acute neurologic episodes; and (4) increased urinary excretion of &#x003b4;-ALA.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="tyrosinemia.GenotypePhenotype_Correlatio">
          <title>Genotype-Phenotype Correlations</title>
          <p>In general, no correlation is observed between clinical presentation and genotype. Acute and chronic forms have been seen in the same families, as well as in unrelated individuals with the same genotype [<xref ref-type="bibr" rid="tyrosinemia.REF.poudrier.1998.119">Poudrier et al 1998</xref>].</p>
          <p>One mechanism that explains this clinical variation is gene reversion. Hepatic nodules removed from livers of individuals with the chronic form of tyrosinemia type I have been shown to have cells that are immunologically positive for FAH protein and to have enzymatic activity for FAH [<xref ref-type="bibr" rid="tyrosinemia.REF.kvittingen.1994.1657">Kvittingen et al 1994</xref>, <xref ref-type="bibr" rid="tyrosinemia.REF.grompe.2001.563">Grompe 2001</xref>]. These seemingly "normal" cells appear to have arisen by gene reversion, that is, the spontaneous self-correction (i.e., reversion or &#x0201c;back-mutation&#x0201d;) of the germline pathogenic variant to the normal gene sequence during somatic cell division.</p>
          <p>Spontaneous somatic variants that suppress the effects of the pathogenic variants and allow for normal or near-normal gene expression in these cells have also been reported [<xref ref-type="bibr" rid="tyrosinemia.REF.bliksrud.2005.406">Bliksrud et al 2005</xref>]. This is a true reversion of the mutated sequence and not the result of maternal cell colonization or maternal cell fusion [<xref ref-type="bibr" rid="tyrosinemia.REF.bergeron.2004.1381">Bergeron et al 2004</xref>]. The &#x0201c;normal&#x0201d; (i.e., reverted) cells have a selective growth advantage because they are no longer at risk for apoptosis from the accumulation of FAA. These foci of revertant &#x0201c;normal&#x0201d; cell colonies comprise many of the liver nodules in untreated individuals with chronic tyrosinemia type I who have a milder biochemical and clinical phenotype [<xref ref-type="bibr" rid="tyrosinemia.REF.kim.2000.791">Kim et al 2000</xref>, <xref ref-type="bibr" rid="tyrosinemia.REF.demers.2003.1313">Demers et al 2003</xref>]. However, the continued production of FAA by the non-revertant mutated cells places the individual at continued risk for hepatocellular carcinoma [<xref ref-type="bibr" rid="tyrosinemia.REF.kim.2000.791">Kim et al 2000</xref>].</p>
          <p>A rare and atypical form of tyrosinemia type I has been reported in a four-month-old Belgian infant with severe liver disease. Liver function studies were abnormal with markedly elevated alpha-fetoprotein, prolonged PT and PTT, and undetectable succinylacetone in urine. Fumarylacetoacetase (FAH) protein and activity was decreased, but not absent. Homozygosity for a unique pathogenic variant, <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.103G&#x0003e;A (p.Ala35Thr)</xref>, was identified [<xref ref-type="bibr" rid="tyrosinemia.REF.cassiman.2009.28">Cassiman et al 2009</xref>].</p>
          <p>Similarly, three sibs who developed chronic liver disease and HCC without detectable blood or urine succinylacetone had deficient FAH activity. The family was of Middle Eastern background and each child was homozygous for <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.424A&#x0003e;G</xref> in <italic toggle="yes">FAH</italic> [<xref ref-type="bibr" rid="tyrosinemia.REF.blackburn.2016.1097">Blackburn et al 2016</xref>].</p>
        </sec>
        <sec id="tyrosinemia.Nomenclature">
          <title>Nomenclature</title>
          <p>Previously used terms referring to tyrosinemia type I include tyrosinosis.</p>
        </sec>
        <sec id="tyrosinemia.Prevalence">
          <title>Prevalence</title>
          <p>In geographic areas without newborn screening, tyrosinemia type I affects approximately one in 100,000 to 120,000 births [<xref ref-type="bibr" rid="tyrosinemia.REF.mitchell.2001">Mitchell et al 2001</xref>]. Because of the inconsistent and confusing nature of its clinical presentation, it is estimated that fewer than 50% of affected individuals are diagnosed while alive.</p>
          <p>In the general US population, the carrier frequency is estimated at 1:150 to 1:100.</p>
          <p>Two regions of the world have a higher than expected frequency of tyrosinemia type I due to the increased frequency of certain pathogenic variants resulting from a founder effect:</p>
          <list list-type="bullet">
            <list-item>
              <p>In the Scandanavian countries (<xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">c.1062+5G&#x0003e;A (IVS 12+5 G&#x0003e;A)</xref>, <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">p.Gly337Ser</xref>, and/or p.249HisfsTer5.5) and in Finland (<xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">p.Trp262Ter</xref>), the birth prevalence is estimated at 1:74,000 and 1:60,000 live births, respectively [<xref ref-type="bibr" rid="tyrosinemia.REF.bliksrud.2012.369">Bliksrud et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>A founder effect from colonization by French settlers is present in the province of Quebec, Canada. The c.1062+5G&#x0003e;A (IVS12+5 G&#x0003e;A) pathogenic variant accounts for 87% of allelic variants in this population. The birth prevalence in the province of Quebec is 1:16,000. In the Saguenay-Lac Saint-Jean region of Quebec, it is 1:1,846 live births. The overall carrier frequency in Quebec is 1:66 based on newborn screening data. The carrier frequency in the Saguenay-Lac St-Jean region is 1:16-1:20.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="tyrosinemia.Genetically_Related_Allelic">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">FAH</italic>.</p>
      </sec>
      <sec id="tyrosinemia.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Children with any of the following presenting findings should be evaluated for tyrosinemia type I (<xref ref-type="table" rid="tyrosinemia.T.differential_diagnosis_of">Table 2</xref>):</p>
        <table-wrap id="tyrosinemia.T.differential_diagnosis_of" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Differential Diagnosis of Tyrosinemia Type I in Infants by Presenting Finding</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Presenting Finding</th>
                <th id="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Differential Diagnosis</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Hypertyrosinemia</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Immature liver</p></list-item><list-item><p>High-protein diet&#x000a0;<sup>1,&#x000a0;2</sup></p></list-item><list-item><p>Tyrosinemia type II (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/276600">276600</ext-link>)</p></list-item><list-item><p>Tyrosinemia type III (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/276710">276710</ext-link>)</p></list-item><list-item><p>Other liver disease</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Hypermethioninemia</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><related-object link-type="booklink" source-id="gene" document-id="homocystinuria" document-type="chapter">Homocystinuria</related-object></p></list-item><list-item><p>Disorders of methionine metabolism</p></list-item><list-item><p>Other liver disease</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Liver disease</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Galactosemia</related-object></p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="hfi" document-type="chapter">Hereditary fructose intolerance</related-object></p></list-item><list-item><p>Fructose 1, 6 biphosphatase deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/229700">229700</ext-link>)</p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="npc" document-type="chapter">Niemann-Pick disease type C</related-object></p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object></p></list-item><list-item><p>Neonatal hemochromatosis (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231100">231100</ext-link>)</p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="hlh" document-type="chapter">Hemophagocytic lymphohistiocytosis</related-object></p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial cytopathies</related-object></p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="cdg" document-type="chapter">Congenital disorders of glycosylation</related-object></p></list-item><list-item><p>Transaldolase deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/606003">606003</ext-link>)</p></list-item><list-item><p>Acetaminophen toxicity</p></list-item><list-item><p>Bacterial infections (sepsis, salmonella, TB)</p></list-item><list-item><p>Viral infections (e.g., CMV, hepatitis A/B, herpes)</p></list-item><list-item><p>Mushroom poisoning&#x000a0;<sup>3</sup></p></list-item><list-item><p>Herbal medicines&#x000a0;<sup>3</sup></p></list-item><list-item><p>Idiosyncratic drug reaction, toxin, vascular/ischemic or infiltrative process&#x000a0;<sup>3</sup></p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Renal syndrome</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><related-object link-type="booklink" source-id="gene" document-id="lowe" document-type="chapter">Lowe syndrome</related-object></p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="ctns" document-type="chapter">Cystinosis</related-object></p></list-item><list-item><p>Renal tubular acidosis</p></list-item><list-item><p>Fanconi syndrome</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Rickets</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><related-object link-type="booklink" source-id="gene" document-id="hops" document-type="chapter">Hypophosphatasia</related-object></p></list-item><list-item><p>Vitamin D deficiency (nutritional/genetic)</p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="rickets-xlh" document-type="chapter">Hypophosphatemic rickets</related-object></p></list-item><list-item><p>Vitamin D-dependent rickets</p></list-item><list-item><p>Fanconi syndrome</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Neurologic crisis</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.differential_diagnosis_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Cerebral hemorrhage/edema</p></list-item><list-item><p>Bacterial/viral meningitis</p></list-item><list-item><p>Hypernatremic dehydration</p></list-item><list-item><p><related-object link-type="booklink" source-id="gene" document-id="aip" document-type="chapter">Acute intermittent porphyria</related-object></p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="tyrosinemia.TF.2.1">
              <label>1. </label>
              <p>
                <xref ref-type="bibr" rid="tyrosinemia.REF.techakittiroj.2005.281">Techakittiroj et al [2005]</xref>
              </p>
            </fn>
            <fn id="tyrosinemia.TF.2.2">
              <label>2. </label>
              <p>Undiluted goat's milk [<xref ref-type="bibr" rid="tyrosinemia.REF.hendriksz.2004.552">Hendriksz &#x00026; Walter 2004</xref>]</p>
            </fn>
            <fn id="tyrosinemia.TF.2.3">
              <label>3. </label>
              <p>
                <xref ref-type="bibr" rid="tyrosinemia.REF.bansal.2004">Bansal &#x00026; Dhawan [2004]</xref>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Tyrosinemia type II</bold> is caused by a defect in tyrosine aminotransferase (TAT) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://enzyme.expasy.org/EC/2.6.1.5">EC 2.6.1.5</ext-link>). Establishing the diagnosis of tyrosinemia type II relies on the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Plasma tyrosine concentration typically greater than 500 &#x000b5;mol/L that may exceed 1000 &#x000b5;mol/L (The concentration of other amino acids is normal.)</p>
          </list-item>
          <list-item>
            <p>Increased excretion of <italic toggle="yes">p</italic>-hydroxyphenylpyruvate, <italic toggle="yes">p</italic>-hydroxyphenyllactate, and <italic toggle="yes">p</italic>-hydroxyphenylacetate and presence of small quantities of <italic toggle="yes">N</italic>-acetyltyrosine and 4-tyramine on urine organic acid analysis</p>
          </list-item>
        </list>
        <p>Affected individuals have painful, non-pruritic, and hyperkeratotic plaques on the soles and palms. The plantar surface of the digits may show marked yellowish thickening associated with the hyperkeratosis. Ophthalmologic involvement is recalcitrant pseudodendritic keratitis [<xref ref-type="bibr" rid="tyrosinemia.REF.macsai.2001.522">Macsai et al 2001</xref>]. Although developmental delay appears to be common, it is unclear if ascertainment bias accounts for this and the reports of neurologic symptoms.</p>
        <p>Findings improve on a diet restricted in tyrosine and phenylalanine [<xref ref-type="bibr" rid="tyrosinemia.REF.ellaway.2001.824">Ellaway et al 2001</xref>].</p>
        <p><bold>Tyrosinemia type III,</bold> the rarest of the tyrosine disorders, is caused by a deficiency of <italic toggle="yes">p</italic>-hydroxyphenylpyruvic acid dioxygenase (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://enzyme.expasy.org/EC/1.13.11.27">EC.1.13.11.27</ext-link>). Plasma concentration of tyrosine ranges from 350 to 650 &#x000b5;mol/L. Excretion of 4-hydroxyphenylpyruvic acid, 4-hydroxyphenyllactate, and 4-hydroxyphenylacetate is increased. The precise quantities vary with protein intake.</p>
        <p>Few individuals with the disorder have been identified, and the clinical phenotype remains ill defined. The first affected individuals came to medical attention because of intellectual disability or ataxia; another was detected on routine screening [<xref ref-type="bibr" rid="tyrosinemia.REF.mitchell.2001">Mitchell et al 2001</xref>]. These individuals, like those with tyrosinemia type II, have no liver involvement but have skin or ocular changes. It remains unclear if tyrosinemia type III is truly associated with cognitive delays or if the association has resulted from ascertainment bias [<xref ref-type="bibr" rid="tyrosinemia.REF.ellaway.2001.824">Ellaway et al 2001</xref>].</p>
        <p>A diet low in phenylalanine and tyrosine can lower plasma tyrosine concentration.</p>
      </sec>
      <sec id="tyrosinemia.Management">
        <title>Management</title>
        <sec id="tyrosinemia.Evaluations_Following_Initia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of a child diagnosed with tyrosinemia type I <bold>on the basis of newborn screening</bold>, the following evaluations are recommended (see <xref ref-type="table" rid="tyrosinemia.T.suggested_guidelines_for_m">Table 3</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p>CBC with platelet count</p>
            </list-item>
            <list-item>
              <p>Serum concentration of electrolytes</p>
            </list-item>
            <list-item>
              <p>Assessment of liver function (PT, PTT, AST, ALT, GGT, serum bilirubin concentration, alkaline phosphatase, and serum AFP).</p>
            </list-item>
          </list>
          <p>For children ascertained <bold>on the basis of clinical symptoms</bold> (see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="tyrosinemia-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material>; pdf), testing should include the evaluations listed above in addition to:</p>
          <list list-type="bullet">
            <list-item>
              <p>Baseline abdominal imagining by CT or MRI (with contrast) to evaluate for liver adenomas or nodules (see <xref ref-type="bibr" rid="tyrosinemia.REF.dubois.1996.845">Dubois et al [1996]</xref>) and renal size;</p>
            </list-item>
            <list-item>
              <p>X-ray of wrist to document presence or absence of rickets.</p>
            </list-item>
          </list>
          <p>Clinical genetics consultation is indicated for all affected individuals.</p>
        </sec>
        <sec id="tyrosinemia.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management guidelines have been published. US recommendations include Chinsky JM et al [in press]; European recommendations include <xref ref-type="bibr" rid="tyrosinemia.REF.de_laet.2013.8">de Laet et al [2013]</xref>.</p>
          <p><bold>Acute management of liver failure.</bold> Children may require respiratory support, appropriate fluid management, and blood products for correction of bleeding diathesis.</p>
          <p><bold>Nitisinone (Orfadin<sup>&#x000ae;</sup>).</bold> 2-(2-nitro-4-trifluoro-methylbenzyol) 1,3 cyclohexanedione (NTBC) blocks parahydroxyphenylpyruvic acid dioxygenase <italic toggle="yes">(p</italic>-HPPD), the second step in the tyrosine degradation pathway, and prevents the accumulation of FAA and its conversion to succinylacetone (<xref ref-type="fig" rid="tyrosinemia.F1">Figure 1</xref>).</p>
          <list list-type="bullet">
            <list-item>
              <p>Nitisinone should be prescribed as soon as the diagnosis of tyrosinemia type I is confirmed.</p>
            </list-item>
            <list-item>
              <p>Nitisinone is generally prescribed at 1.0 mg/kg/day; individual requirements may vary. Dosage should be adjusted to maintain blood nitisinone levels between 40 and 60 &#x000b5;mol/L, which theoretically blocks more than 99% of <italic toggle="yes">p</italic>-HPPD activity. Rarely, an individual may require higher blood levels of nitisinone (70 &#x000b5;mol/L) to suppress succinylacetone excretion. As long as blood concentration of nitisinone is within the therapeutic range, urine succinylacetone does not need to be measured.</p>
            </list-item>
            <list-item>
              <p>Nitisinone is typically given in two divided doses; however, because of the long half-life (50-60 hours), affected individuals who are older than one year and stable may maintain adequate therapy with 1x/day dosing [<xref ref-type="bibr" rid="tyrosinemia.REF.schlune.2012.831">Schlune et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Rare side effects of nitisinone have included: transient low platelet count and transient low neutrophil count that resolved without intervention; and photophobia that resolved with stricter dietary control and subsequent lowering of blood tyrosine concentrations.</p>
            </list-item>
          </list>
          <p><bold>Low-tyrosine diet.</bold> Nitisinone increases blood concentration of tyrosine, necessitating a low-tyrosine diet to prevent tyrosine crystals from forming in the cornea.</p>
          <list list-type="bullet">
            <list-item>
              <p>Dietary management should be started immediately upon diagnosis and should provide a nutritionally complete diet with controlled intakes of phenylalanine and tyrosine using a vegetarian diet with low-protein foods and a medical formula such as Tyrex<sup>&#x000ae;</sup> (Ross) or Tyros-1<sup>&#x000ae;</sup> (Mead Johnson).</p>
            </list-item>
            <list-item>
              <p>Phenylalanine and tyrosine requirements are interdependent and vary from individual to individual and within the same individual depending on growth rate, adequacy of energy and protein intakes, and state of health. With appropriate dietary management, plasma tyrosine concentration should be 300-600 &#x000b5;mol/L, regardless of age; plasma phenylalanine concentration should be 20-80 &#x000b5;mol/L (0.3-1.3 mg/dL). If the blood concentration of phenylalanine is too low (&#x0003c;20 &#x000b5;mol/L), additional protein should be added to the diet from milk or foods.</p>
            </list-item>
          </list>
          <p><bold>Liver transplantation.</bold> Prior to the availability of nitisinone for the treatment of tyrosinemia type I, the only definitive therapy was liver transplantation.</p>
          <list list-type="bullet">
            <list-item>
              <p>Liver transplantation should be reserved for those children who (1) have severe liver failure at clinical presentation and fail to respond to nitisinone therapy or (2) have documented evidence of malignant changes in hepatic tissue [<xref ref-type="bibr" rid="tyrosinemia.REF.bartlett.2014.745">Bartlett et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Transplant recipients require long-term immunosuppression. Mortality associated with liver transplantation in young children is approximately 10%.</p>
            </list-item>
            <list-item>
              <p>Transplant recipients may also benefit from low-dose (0.1mg/kg/day) nitisinone therapy to prevent continued renal tubular and glomerular dysfunction resulting from persistence of succinylacetone in the plasma and urine [<xref ref-type="bibr" rid="tyrosinemia.REF.bartlett.2013.15">Bartlett et al 2013</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="tyrosinemia.Prevention_of_Primary_Manife">
          <title>Prevention of Primary Manifestations</title>
          <p>Treatment with nitisinone (Orfadin<sup>&#x000ae;</sup>) should begin as soon as the diagnosis is confirmed.</p>
        </sec>
        <sec id="tyrosinemia.Prevention_of_Secondary_Comp">
          <title>Prevention of Secondary Complications</title>
          <p>Because carnitine deficiency secondary to the renal tubular Fanconi syndrome can cause skeletal muscle weakness, serum concentration of carnitine should be measured so that carnitine deficiency, if identified, can be treated [<xref ref-type="bibr" rid="tyrosinemia.REF.nissenkorn.2001.642">Nissenkorn et al 2001</xref>].</p>
          <p>Osteoporosis and rickets resulting from renal tubular damage are treated by correction of acidosis, restoring of calcium and phosphate balance, and administration of 25-hydroxy-vitamin D.</p>
        </sec>
        <sec id="tyrosinemia.Surveillance">
          <title>Surveillance</title>
          <p>Frequent evaluation of the following parameters is typical in the management of individuals with tyrosinemia type I (<xref ref-type="table" rid="tyrosinemia.T.suggested_guidelines_for_m">Table 3</xref>) [CR Scott, personal recommendations].</p>
          <table-wrap id="tyrosinemia.T.suggested_guidelines_for_m" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Suggested Guidelines for Monitoring in Individuals with Tyrosinemia Type I Diagnosed by Newborn Screening</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1">Evaluation</th>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2">Initiation of Therapy (Baseline)</th>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">First 6 Months:</th>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4">After 6 Months of Rx: Every 6-12 Months</th>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5">After 2 Years of Rx: Every 6-12 Months</th>
                  <th id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6">As Clinically Indicated</th>
                </tr>
                <tr>
                  <th headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3" id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Monthly</th>
                  <th headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3" id="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Every 3 months</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Tyrosinemia type I markers</bold>
                  </td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Plasma concentration of methionine, phenylalanine, tyrosine</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">x</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">or X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Blood / urine succinylacetone</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">X<break/>(urine)</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">or X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Blood nitisinone concentration</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">or X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>CBC</bold>
                  </td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Hemoglobin, hematocrit, WBC, platelet count</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">or X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" rowspan="6" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Liver <break/>evaluation</bold>
                  </td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Serum AFP concentration</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">PT/PTT</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">X<break/>(until normal)</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Bilirubin</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">ALT/AST/GGT</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">X<break/>(until normal)</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Alkaline phosphatase</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">X<break/>(until normal)</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">CT or MRI&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Renal <break/>studies</bold>
                  </td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">BUN / creatinine</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Urine: PO4, Ca, Prot/Cr ratio</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
                <tr>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Skeletal evaluation</bold>
                  </td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">X-ray of wrist (for rickets)</td>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_3 hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_tyrosinemia.T.suggested_guidelines_for_m_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">X</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>AFP = alpha-fetoprotein</p>
              </fn>
              <fn>
                <p>ALT/AST = alanine transaminase/aspartate transaminase</p>
              </fn>
              <fn>
                <p>BUN = blood urea nitrogen</p>
              </fn>
              <fn>
                <p>CBC = complete blood count</p>
              </fn>
              <fn>
                <p>GGT = gamma-glutamyl transferase</p>
              </fn>
              <fn>
                <p>PT/PTT = prothrombin time/partial thromboplastin time</p>
              </fn>
              <fn id="tyrosinemia.TF.3.1">
                <label>1. </label>
                <p>MRI with contrast to evaluate for liver adenomas or nodules and for kidney size</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>For monitoring children diagnosed based on clinical presention, see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="tyrosinemia-Table4.pdf" content-type="local-data">Table 4</inline-supplementary-material> (pdf).</p>
          <p>For alternative management recommendations, see <xref ref-type="bibr" rid="tyrosinemia.REF.de_laet.2013.8">de Laet et al [2013]</xref>.</p>
        </sec>
        <sec id="tyrosinemia.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid inappropriate protein intake.</p>
        </sec>
        <sec id="tyrosinemia.Evaluation_of_Relatives_at_R">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known. Prenatal testing can be used to clarify the genetic status of at-risk sibs before birth.</p>
            </list-item>
            <list-item>
              <p>Blood or urine succinylacetone analysis as soon as possible after birth if prenatal testing was not performed. This allows prompt initiation of treatment, as postnatal genetic testing results may not be available in a timely fashion.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variants in the family are not known, consideration of analysis for urine succinylacetone in healthy older sibs</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="tyrosinemia.Related_Genetic_Counseling_I">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="tyrosinemia.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Little data exist on the use of nitisinone during human pregnancy. Speculation would assume that the pregnant woman remains safe from untoward events; however, the developing fetus may be at risk because of alterations in tyrosine metabolism.</p>
          <p>At least two women have given birth to healthy infants while receiving therapeutic doses of nitisinone [<xref ref-type="bibr" rid="tyrosinemia.REF.garcia_segarra.2010.s507">Garcia Segarra et al 2010</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>In one instance the affected mother gave birth to an unaffected infant who is reported to be healthy and developing normally at age 2.5 years [<xref ref-type="bibr" rid="tyrosinemia.REF.garcia_segarra.2010.s507">Garcia Segarra et al 2010</xref>, <xref ref-type="bibr" rid="tyrosinemia.REF.vanclooster.2012.27">Vanclooster et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>In another instance, an affected woman gave birth to an affected child. The child is reported to have normal growth and development at age seven months [<xref ref-type="bibr" rid="tyrosinemia.REF.garcia_segarra.2010.s507">Garcia Segarra et al 2010</xref>]. The authors speculate that the affected child was protected from in utero liver damage by maternal treatment with nitisinone during pregnancy.</p>
            </list-item>
          </list>
          <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mothertobaby.org">www.mothertobaby.org</ext-link> for more information on medication exposure during pregnancy.</p>
        </sec>
        <sec id="tyrosinemia.Therapies_Under_Investigatio">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="tyrosinemia.Other">
          <title>Other</title>
          <p>Prior to the availability of nitisinone, the only available non-transplant therapy was a diet limiting the availability of phenylalorine and tyrosine. Although modestly helpful, recurrent episodes of neurologic crises and progression of liver disease occurred. Average survival was less than age ten years.</p>
        </sec>
      </sec>
      <sec id="tyrosinemia.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="tyrosinemia.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Tyrosinemia type I is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="tyrosinemia.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">FAH</italic> pathogenic allelic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with tyrosinemia type I are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">FAH</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a <italic toggle="yes">FAH</italic> pathogenic variant.</p>
          <p>
            <bold>Carrier (Heterozygote) Detection</bold>
          </p>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">FAH</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="tyrosinemia.Related_Genetic_Counseling_I">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="tyrosinemia.Evaluation_of_Relatives_at_R">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="tyrosinemia.Prenatal_Testing_and_Preimpl">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">FAH</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for tyrosinemia type I are possible.</p>
          <p><bold>Biochemical testing.</bold> Prenatal diagnosis for pregnancies at 25% risk is possible by detection of succinylacetone in amniotic fluid obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation. Although detection of succinylacetone in amniotic fluid is diagnostic, false negative results have been reported; thus, this method should only be used by laboratories consistently able to identify succinylacetone at low levels by stable isotope detection. Because of these issues with biochemical testing, molecular genetic testing is the preferred method of prenatal diagnosis.</p>
        </sec>
      </sec>
      <sec id="tyrosinemia.Resources">
        <title>Resources</title>
      </sec>
      <sec id="tyrosinemia.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">FAH</italic> is approximately 35 kbp in size and comprises 14 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="tyrosinemia" object-id="tyrosinemia.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> A single pseudodeficiency allele, c.1021C&#x0003e;T (p.Arg341Trp) leads to decreased FAH enzyme activity and very little immunoreactive protein, but adequate amounts of FAH mRNA [<xref ref-type="bibr" rid="tyrosinemia.REF.rootwelt.1994">Rootwelt et al 1994</xref>].</p>
        <p><bold>Pathogenic variants.</bold> See <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">Table 5</xref>. Pathogenic missense, nonsense, and splice site variants, as well as small deletions and indels of <italic toggle="yes">FAH,</italic> have been reported. <xref ref-type="bibr" rid="tyrosinemia.REF.park.2009.930">Park et al [2009]</xref> reported a large deletion involving <italic toggle="yes">FAH.</italic></p>
        <p>The following population-specific pathogenic variants result from founder effects or genetic drift [<xref ref-type="bibr" rid="tyrosinemia.REF.angileri.2015.43">Angileri et al 2015</xref>] (see <xref ref-type="table" rid="tyrosinemia.T.fah_variants_discussed_in">Table 5</xref>):</p>
        <list list-type="bullet">
          <list-item>
            <p>Ashkenazi Jewish: p.Pro261Leu</p>
          </list-item>
          <list-item>
            <p>Finnish: p.Trp262Ter</p>
          </list-item>
          <list-item>
            <p>French Canadian: c.1062+5G&#x0003e;A</p>
          </list-item>
          <list-item>
            <p>Pakistani: p.Gln64His</p>
          </list-item>
          <list-item>
            <p>Scandinavian: p.Gly337Ser</p>
          </list-item>
          <list-item>
            <p>Turkish: p.Asp233Val</p>
          </list-item>
          <list-item>
            <p>Northern European: c.1062+5G&#x0003e;A</p>
          </list-item>
          <list-item>
            <p>Southern European: c.554-1G&#x0003e;T</p>
          </list-item>
        </list>
        <table-wrap id="tyrosinemia.T.fah_variants_discussed_in" orientation="portrait" position="anchor">
          <label>Table 5. </label>
          <caption>
            <p><italic toggle="yes">FAH</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant<break/>Classification</th>
                <th id="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Pseudodeficiency</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1021C&#x0003e;T</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg341Trp</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_4" rowspan="11" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000137.1">NM_000137.1</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000128.1">NP_000128.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_1" rowspan="10" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.103G&#x0003e;A</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala35Thr</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.192G&#x0003e;T</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln64His</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.424A&#x0003e;G</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg142Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.554-1G&#x0003e;T<break/>(IVS6-1G&#x0003e;T)</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.607-6T&#x0003e;G<break/>(IVS7-6T&#x0003e;G)</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.698A&#x0003e;T</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp233Val</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.782C&#x0003e;T</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro261Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.786G&#x0003e;A</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp262Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1009G&#x0003e;A</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly337Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1062+5G&#x0003e;A<break/>(IVS12+5 G&#x0003e;A)</td>
                <td headers="hd_h_tyrosinemia.T.fah_variants_discussed_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="tyrosinemia.TF.5.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>For additional pathogenic variants identified in North American patients, see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="tyrosinemia-Table6.pdf" content-type="local-data">Table 6</inline-supplementary-material> (pdf).</p>
        <p><bold>Normal gene product.</bold> FAH is a cytosolic protein that acts as a homodimer and has a molecular weight of approximately 80 kd. The wild-type FAH has a Km for FAA of about 3.5 &#x003bc;mol/L. FAH catalyzes the conversion of FAA to fumarate and acetoacetate and the conversion of succinylacetoacetate to succinate and acetoacetate.</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic missense, nonsense, and splice site variants result in loss of FAH enzyme activity, leading to an intracellular accumulation of FAA resulting in cellular damage and apoptosis.</p>
      </sec>
      <sec id="tyrosinemia.References">
        <title>References</title>
        <sec id="tyrosinemia.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="tyrosinemia.Literature_Cited.reflist0">
            <ref id="tyrosinemia.REF.ahmad.2002.266">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ahmad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teckman</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lueder</surname>
                    <given-names>GT</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Corneal opacities associated with NTBC treatment.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>134</volume>
                <fpage>266</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12140036</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.angileri.2015.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Angileri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergeron</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrow</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutchin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <article-title>Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1.</article-title>
                <source>JIMD Rep.</source>
                <year>2015</year>
                <volume>19</volume>
                <fpage>43</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">25681080</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.bansal.2004">
              <mixed-citation publication-type="book">Bansal S, Dhawan A. Acute liver failure. In: Walker WA, Kleinman RE, Sherman PM, Shneider BL, Sanderson IR, eds. <italic toggle="yes">Pediatric Gastrointestinal Disease - Pathophysiology, Diagnosis, Management.</italic> 4 ed. Ch 58. Hamilton, Ontario: BC Decker, Inc; 2004:1491-507.</mixed-citation>
            </ref>
            <ref id="tyrosinemia.REF.bartlett.2014.745">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bartlett</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newsome</surname>
                    <given-names>PN</given-names>
                  </name>
                </person-group>
                <article-title>Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2014</year>
                <volume>37</volume>
                <fpage>745</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">24515874</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.bartlett.2013.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bartlett</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preece</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newsome</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>15</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">22456946</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.baumann.2005.131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preece</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hyperinsulinism in tyrosinaemia type I.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>28</volume>
                <fpage>131</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15877201</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.bergeron.2004.1381">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergeron</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morissette</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>No evidence of maternal cell colonization in reverted liver nodules of tyrosinemia type I patients.</article-title>
                <source>Gastroenterology</source>
                <volume>127</volume>
                <fpage>1381</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15521007</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.blackburn.2016.1097">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blackburn</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hickey</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nace</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giama</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraft</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordner</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaiteerakij</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCormick</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radulovic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torbenson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortorelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindor</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oglesbee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Qabandi</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grompe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gavrilov</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Youssef</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atwal</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klee</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ekker</surname>
                    <given-names>SC</given-names>
                  </name>
                </person-group>
                <article-title>Silent tyrosinemia type I without elevated tyrosine or succinylacetone associated with liver cirrhosis and hepatocellular carcinoma.</article-title>
                <source>Hum Mutat.</source>
                <year>2016</year>
                <volume>37</volume>
                <fpage>1097</fpage>
                <lpage>105</lpage>
                <pub-id pub-id-type="pmid">27397503</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.bliksrud.2012.369">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bliksrud</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodtkorb</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Backe</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woldseth</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rootwelt</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene.</article-title>
                <source>Scand J Clin Lab Invest.</source>
                <year>2012</year>
                <volume>72</volume>
                <fpage>369</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">22554029</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.bliksrud.2005.406">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bliksrud</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodtkorb</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kvittingen</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.</article-title>
                <source>J Mol Med</source>
                <volume>83</volume>
                <fpage>406</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">15759101</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.cassiman.2009.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cassiman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeevaert</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kvittingen</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaeken</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <volume>4</volume>
                <fpage>28</fpage>
                <pub-id pub-id-type="pmid">20003495</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.demers.2003.1313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Demers</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.</article-title>
                <source>Hum Pathol</source>
                <volume>34</volume>
                <fpage>1313</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">14691918</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.dubois.1996.845">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dubois</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patriquin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradis</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forget</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filiatrault</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grignon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St-Vil</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Imaging features of type 1 hereditary tyrosinemia: a review of 30 patients.</article-title>
                <source>Pediatr Radiol</source>
                <volume>26</volume>
                <fpage>845</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">8929295</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.ellaway.2001.824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ellaway</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Standing</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preece</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploechl</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugarte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trefz</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Outcome of tyrosinaemia type III.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>24</volume>
                <fpage>824</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">11916315</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.elpeleg.2002.80">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>ON</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zughayar</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurvitz</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.</article-title>
                <source>Hum Mutat</source>
                <volume>19</volume>
                <fpage>80</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">11754109</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.endo.2002.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Endo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>25</volume>
                <fpage>227</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">12137232</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.garcia_segarra.2010.s507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garcia Segarra</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoist</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gren&#x000e8;che</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davit-Spraul</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogier de Baulny</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Maternal and fetal tyrosinemia type I.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2010</year>
                <volume>33</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S507</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">23250512</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.gigu_re.2005">
              <mixed-citation publication-type="confproc">Gigu&#x000e8;re Y, Ruel J, Belanger N, Grenier A, Laberge C, Quebec Neonatal Blood Screening Programme, CHUL du CHUQ, Quebec, Canada. Neonatal mass screening for hereditary tyrosinemia type 1 in Quebec: a historical perspective (1970-2005). Portland, OR: Newborn Screening and Genetic Testing Symposium. 2005.</mixed-citation>
            </ref>
            <ref id="tyrosinemia.REF.grompe.2001.563">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grompe</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The pathophysiology and treatment of hereditary tyrosinemia type 1.</article-title>
                <source>Semin Liver Dis</source>
                <volume>21</volume>
                <fpage>563</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">11745044</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.hegarty.2015.1387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hegarty</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadzic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhawan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King's College Hospital experience.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2015</year>
                <volume>174</volume>
                <fpage>1387</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">25902754</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.hendriksz.2004.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hendriksz</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>JH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Feeding infants with undiluted goat's milk can mimic tyrosinaemia type 1.</article-title>
                <source>Acta Paediatr</source>
                <volume>93</volume>
                <fpage>552</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15188986</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.holme.2000.805">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindstedt</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Nontransplant treatment of tyrosinemia.</article-title>
                <source>Clin Liver Dis</source>
                <volume>4</volume>
                <fpage>805</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">11232358</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.kim.2000.791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kupke</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ierardi-Curto</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poudrier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Astous</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>HL</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>23</volume>
                <fpage>791</fpage>
                <lpage>804</lpage>
                <pub-id pub-id-type="pmid">11196105</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.kvittingen.1994.1657">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kvittingen</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rootwelt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandtzaeg</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Self-induced correction of the genetic defect in tyrosinemia type I.</article-title>
                <source>J Clin Invest</source>
                <volume>94</volume>
                <fpage>1657</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">7929843</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.de_laet.2013.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Laet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Baulny</surname>
                    <given-names>HO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiekerk&#x000f6;tter</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Recommendations for the management of tyrosinaemia type 1.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>8</fpage>
                <pub-id pub-id-type="pmid">23311542</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.larochelle.2012.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Larochelle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alvarez</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bussi&#x000e8;res</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chevalier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallaire</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubois</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faucher</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenyves</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodyer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grenier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laframboise</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindstedt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maranda</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melan&#x000e7;on</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merouani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parizeault</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelletier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Qu&#x000e9;bec.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>107</volume>
                <fpage>49</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">22885033</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.macsai.2001.522">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Macsai</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinkle</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hummel</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulhern</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rootman</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Tyrosinemia type II: nine cases of ocular signs and symptoms.</article-title>
                <source>Am J Ophthalmol</source>
                <volume>132</volume>
                <fpage>522</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11589874</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.masurelpaulet.2008.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masurel-Paulet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poggi-Bach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernard</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guffon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbelaere</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Baulny</surname>
                    <given-names>HO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Touati</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>NTBC treatment in tyrosinaemia type 1: long-term outcome in French patients.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>31</volume>
                <fpage>81</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18214711</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.mckiernan.2006.743">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Nitisinone in the treatment of hereditary tyrosinaemia type 1.</article-title>
                <source>Drugs</source>
                <volume>66</volume>
                <fpage>743</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">16706549</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.mitchell.1990.432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larochelle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaud</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grenier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogier</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauthier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanasse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larbrisseau</surname>
                    <given-names>A</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>1990</year>
                <article-title>Neurologic crises in hereditary tyrosinemia.</article-title>
                <source>N Engl J Med</source>
                <volume>322</volume>
                <fpage>432</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">2153931</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.mitchell.2001">
              <mixed-citation publication-type="book">Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. New York, NY: McGraw Hill; 2001:1777-806</mixed-citation>
            </ref>
            <ref id="tyrosinemia.REF.nissenkorn.2001.642">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nissenkorn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vardi</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katzir</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerman-Sagie</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Carnitine-deficient myopathy as a presentation of tyrosinemia type I.</article-title>
                <source>J Child Neurol</source>
                <volume>16</volume>
                <fpage>642</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11575602</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.park.2009.930">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ki</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>YW</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1.</article-title>
                <source>Clin Chem Lab Med.</source>
                <volume>47</volume>
                <fpage>930</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">19569981</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.poudrier.1998.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poudrier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larochelle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.</article-title>
                <source>Mol Genet Metab</source>
                <volume>64</volume>
                <fpage>119</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">9705236</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.poudrier.1996.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poudrier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St-Louis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prevost</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larochelle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanguay</surname>
                    <given-names>RM</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Frequency of the IVS12 + 5G--&#x0003e;A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean.</article-title>
                <source>Prenat Diagn</source>
                <volume>16</volume>
                <fpage>59</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">8821854</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.rootwelt.1994">
              <mixed-citation publication-type="web">Rootwelt H, Brodtkorb E, Kvittingen EA. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/7977370">Am J Hum Genet.</ext-link> 1994;55:1122-7.</mixed-citation>
            </ref>
            <ref id="tyrosinemia.REF.sassa.1983.625">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sassa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kappas</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.</article-title>
                <source>J Clin Invest</source>
                <volume>71</volume>
                <fpage>625</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">6826727</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.schlune.2012.831">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schlune</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thimm</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herebian</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiekerkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Single dose NTBC-treatment of hereditary tyrosinemia type I.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>831</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22307209</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.schulze.2001.1424">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulze</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frommhold</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I.</article-title>
                <source>Clin Chem</source>
                <volume>47</volume>
                <fpage>1424</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11468232</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.techakittiroj.2005.281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Techakittiroj</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thoene</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>High protein diet mimics hypertyrosinemia in newborn infants.</article-title>
                <source>J Pediatr</source>
                <volume>146</volume>
                <fpage>281</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15689925</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.vanclooster.2012.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vanclooster</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devlieger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meersseman</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spraul</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerckhove</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vermeersch</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meulemans</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allegaert</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassiman</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancy during nitisinone treatment for tyrosinaemia type I: first human experience.</article-title>
                <source>JIMD Rep.</source>
                <year>2012</year>
                <volume>5</volume>
                <fpage>27</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">23430914</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.van_spronsen.2005.90">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bijleveld</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Maldegem</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifl).</article-title>
                <source>J Pediatr Gastroenterol Nutr</source>
                <volume>40</volume>
                <fpage>90</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15625434</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.van_spronsen.1994.1187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomasse</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fidler</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heymans</surname>
                    <given-names>HS</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.</article-title>
                <source>Hepatology</source>
                <volume>20</volume>
                <fpage>1187</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">7927251</pub-id>
              </element-citation>
            </ref>
            <ref id="tyrosinemia.REF.vogel.2004.433">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Den Berg</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Dhalimy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groopman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ou</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryabinina</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iordanov</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finegold</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grompe</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.</article-title>
                <source>Hepatology</source>
                <volume>39</volume>
                <fpage>433</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">14767996</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="tyrosinemia.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="tyrosinemia.Suggested_Reading.reflist0">
            <ref id="tyrosinemia.REF.mitchell">
              <mixed-citation publication-type="book">Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chap 79. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="tyrosinemia.REF.thimm.2011.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thimm</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herebian</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speikerkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.</article-title>
                <source>Mol Genet Metab</source>
                <volume>102</volume>
                <fpage>122</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21112803</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="tyrosinemia.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="tyrosinemia.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://depts.washington.edu/tyros/">University of Washington Biochemical Genetics Clinic Tyrosinemia Home Page</ext-link>
          </p>
        </sec>
        <sec id="tyrosinemia.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Supported by grants from the Food and Drug Administration (FD-4-001445) and Rare Disease Therapeutics. The authors are appreciative of the collaboration and discussions with Dr. Grant Mitchell of Montreal, Canada, and Dr. Sven Lindstedt and Dr. Elisabeth Holme of Gothenburg, Sweden.</p>
        </sec>
        <sec id="tyrosinemia.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 May 2017 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>17 July 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>25 August 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 October 2008 (cg) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>24 July 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>29 June 2005 (crs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="tyrosinemia.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>The tyrosine catabolic pathway</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tyrosinemia-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="tyrosinemia.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Survival of children with tyrosinemia before 1992 [<xref ref-type="bibr" rid="tyrosinemia.REF.van_spronsen.1994.1187">van Spronsen et al 1994</xref>]</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tyrosinemia-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
